
Please try another search
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer’s disease, as well as in phase 3 to treat parkinson’s disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer’s disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
Michael M. B. Hoffman | 75 | 2014 | Independent Chairman of the Board |
Jeffrey L. Cummings | 75 | - | Chief Medical Advisor & Member of Scientific Advisory Board |
Sidney Strickland | - | 2017 | Chairman of Scientific Advisory Board |
Mark K. White | 69 | 2016 | Director |
Reid S. McCarthy | 71 | 2021 | Independent Director |
Gregory A. Petsko | - | 2017 | Member of Scientific Advisory Board |
Claudine E. Bruck | 70 | 2015 | Independent Director |
Maria L. Maccecchini | 74 | 2008 | Founder, CEO, President & Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review